Blue Stream Laboratories Adds Capacity
News Nov 05, 2015
Blue Stream Laboratories is expanding into new office and lab space, adjacent to its current facility, to handle the continued growth of its biosimilars services. Last year, the company moved into new space in Woburn to double the capacity of its prior Cambridge facility.
Blue Stream will exhibit at Booth 8 at the Well Characterized Biologicals Conference from Nov. 9-10 at the Hyatt Regency Reston VA.
Having provided characterization services for 10 of the top biosimilar products in development, Blue Stream offers a complete suite of analytical solutions for biosimilar product development from initial product screening to biosimilar/originator comparability to comprehensive characterization including primary and secondary/tertiary structure, glycosylation/PTMs, and activity.
The biosimilar segment continues to perform well for the company. In 2014, Blue Stream recorded a 60 percent increase in revenue over the prior year, along with a 50 percent increase in facility size, and a 30 percent expansion of its research and development capabilities. This growth was significantly driven by Blue Stream’s biosimilars services.
“The market for biosimilars continues to grow, with consensus of reaching at least $20 billion within the next few years. Blue Stream has significant biosimilar expertise, and we continue to invest in the people, equipment and infrastructure to develop innovative methods, improve quality and extend our expertise,” said William Rash, VP, Sales and Marketing of Blue Stream Laboratories.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018